UCB on Tuesday announced that it entered into a strategic partnership agreement with Synosia to develop neurology drugs. Under the agreement, UCB will receive the exclusive worldwide rights to the development of SYN-115 and the rights to SYN-118 for non-orphan indications, both of which are currently in mid-stage trials for the treatment of Parkinson's disease. The deal also allows for additional compounds from either company's pipeline to be added to the collaboration.
Reference Articles
Accord entre UCB et Synosia Therapeutics dans le domaine de la neurologie - (La Libre)
UCB, Synosia announce strategic partnership in neurology - (Stock Markets Review)
UCB and Synosia Therapeutics sign strategic alliance in neurology - (The FINANCIAL)
UCB and Synosia Therapeutics sign strategic alliance in neurology - (UCB)
**Published in "First Word"
No comments:
Post a Comment